The Clinically Approved Antifungal Drug Posaconazole Inhibits Human Cytomegalovirus Replication

Beatrice Mercorelli,a# Anna Luganini,b Marta Celegato,a Giorgio Palù,a Giorgio Gribaudo,b Galina I. Lepesheva,c Arianna Loregian a#

aDepartment of Molecular Medicine, University of Padua, Padua, Italy
bDepartment of Life Sciences and Systems Biology, University of Turin, Turin, Italy
cDepartment of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN.

Running Head: HCMV Inhibition by Posaconazole

#Address correspondence to Arianna Loregian, arianna.loregian@unipd.it and Beatrice Mercorelli beatrice.mercorelli@unipd.it.
ABSTRACT

Posaconazole (PCZ) is a clinically approved drug used predominantly for prophylaxis and salvage therapy of fungal infections. Here, we report its previously undescribed anti-human cytomegalovirus (HCMV) activity. By antiviral assays we demonstrated that PCZ, along with other azolic antifungals, has a broad anti-HCMV activity being active against different strains including low-passage clinical isolates and strains resistant to viral DNA polymerase inhibitors. Using a pharmacological approach, we identified the inhibition of human cytochrome P450 51 (hCYP51) or lanosterol 14α demethylase, a cellular target of posaconazole in infected cells, as a mechanism of anti-HCMV activity of the drug. Indeed, hCYP51 expression was stimulated upon HCMV infection and the inhibition of its enzymatic activity by either a lanosterol analog (VFV) or PCZ decreased HCMV yield and infectivity of released virus particles. Importantly, we observed that the activity of the first line anti-HCMV drug ganciclovir was tenfold boosted by PCZ and that GCV and PCZ act synergistically in inhibiting HCMV replication. Taken together, these findings suggest that this clinically approved drug deserves further investigation in the development of host-directed antiviral strategies as a candidate anti-HCMV drug with a dual antimicrobial effect.

KEYWORDS: HCMV, antiviral, posaconazole, human CYP51, drug repurposing, synergism.
Human cytomegalovirus (HCMV) is a ubiquitous beta-herpesvirus that infects from 60% to nearly 80% of the human population worldwide and establishes a life-long persistence in the host characterized by sporadic reactivations in healthy individuals (1). HCMV is also a major opportunistic human pathogen, which causes life-threatening diseases in subjects with acquired or developmental immunodeficiency, such as transplant recipients or immune naïve fetuses. Indeed, HCMV causes deafness and neurological disorders in approximately 0.1% of congenital infections (2). Moreover, HCMV has been suggested as a cofactor of vascular diseases and immune senescence (3).

To date, to prevent and treat HCMV infections, there is no vaccine available, and only a limited number of drugs are licensed for treatment: ganciclovir (GCV), its oral prodrug valganciclovir, foscarnet, acyclovir, its prodrug valacyclovir, cidofovir, and the recently approved letermovir (4,5). Currently, all the available anti-HCMV drugs target virus-encoded proteins, i.e., the DNA polymerase and the terminase (5). The clinical use of these antivirals can have several drawbacks, such as an unfavorable safety profile characterized by severe acute or long-term toxicity and poor oral bioavailability (4). Moreover, no drug has been approved for the treatment of congenital infection (6) and the management of HCMV infections can be further complicated by the emergence of drug-resistant HCMV strains (7,8). For all these reasons, there is still a strong need to develop new, safe, and effective antiviral compounds, possibly endowed with a new mechanism of action.

HCMV, like many other viruses, hijacks several cellular pathways and deeply alters many host physiological processes in order to replicate efficiently (9). Thus, the development of host-directed antiviral strategies could be an alternative or an additional approach to treat HCMV-associated diseases (10), as well as to overcome viral resistance issues. In this
regard, drug repurposing can represent a powerful strategy for the identification of host pathways and factors playing a role during viral replication (11-13). Based on this rationale, we followed this strategy to identify new compounds and targets for anti-HCMV intervention through a drug screening and follow-up studies that identified several novel HCMV inhibitors, including both approved drugs and natural compounds (12,14,15).

Here, we report the discovery of the previously undescribed anti-HCMV activity of posaconazole (PCZ), a drug approved for the prophylaxis and salvage therapy of systemic fungal infections. Our study stems from the observation that drugs belonging to the class of azolic antifungals were identified in two previous independent drug repurposing screenings for inhibitors of HCMV replication (12,16,17). Starting from this observation, we initially evaluated the antiviral activity of a panel of azolic antifungals used both topically and for the treatment of invasive fungal infections. PCZ, which was not present in our original screened library, showed an interesting anti-HCMV activity, thus we decided to characterize further its antiviral mechanism. In the recent years, the antiviral properties of azolic antifungals has been an emerging topic and PCZ, together with itraconazole, was found to have activity against both positive-stranded RNA viruses, such as picornaviruses and flaviviruses (11,18,19), and against negative-stranded RNA viruses, such as Ebola virus and influenza virus (20,21).

We investigated deeper the anti-HCMV activity of PCZ and found that its antiviral activity was related to its inhibitory activity against human cytochrome P450 51 (hCYP51, or lanosterol 14α demethylase). This enzyme is the most conserved cytochrome P450, as well as the only that catalyzes demethylation of lanosterol (22), being involved in both cholesterogenesis and synthesis of essential regulatory sterols during meiosis (23). Fungal
CYP51 is the target of PCZ and other antifungals in the treatment of mycosis, however our study suggests that human CYP51 is involved in the antiviral mechanism of PCZ against HCMV.

Noteworthy, our data indicate that a combination of PCZ with GCV, the gold standard for anti-HCMV therapy, greatly potentiates the antiviral effect of the latter and is synergistic in inhibiting HCMV replication in infected cells. Thus, this study provides the rationale for a possible clinical validation of the anti-HCMV activity of PCZ alone or in combination with GCV.

RESULTS

Anti-human cytomegalovirus activity of approved azolic antifungals. In a drug repurposing campaign, we previously identified a series of molecules endowed with anti-HCMV activity, among which we noticed an overrepresentation of drugs belonging to the class of azolic antifungals (12). To extend this knowledge, a more complete panel of azolic antifungal drugs was analyzed for anti-HCMV activity (Table 1). As shown in Fig. 1A, in plaque reduction assays (PRA), posaconazole (PCZ) and ketoconazole (KTZ) showed a dose-dependent inhibitory effect on HCMV AD169 replication in HFF cells, similarly to what we previously reported for clotrimazole, econazole, and miconazole (12). On the other hand, under the same experimental conditions, fluconazole (FCZ), voriconazole (VCZ), and itraconazole (ITZ) did not exhibit significant anti-HCMV activity (Fig. 1B).

Then, to exclude the possibility that the antiviral activity of PCZ might be due to cytotoxicity, its effect on the viability of uninfected HFFs cells was evaluated by MTT
assays. As reported in Table 1, we found that the antiviral activity of posaconazole was not due to cytotoxicity of the target cells, since a significant toxic effect was not observed at concentrations up to 250 µM.

**Broad anti-HCMV activity of posaconazole and other antifungals.** To investigate the spectrum of anti-HCMV activity of PCZ and of other antifungals, we repeated the antiviral assays with a panel of HCMV strains, including three different low passage-number clinical isolates (TB40-UL32-EGFP, VR1814, and 388438U). As reported in Figure 2, the anti-HCMV activity of PCZ was not dependent on the viral strain, since the EC₅₀ values obtained with different HCMV strains were comparable (Table 2). Next, we evaluated the activity of PCZ against HCMV strains resistant to the available viral DNA polymerase inhibitors, as the emergence of drug resistance is an increasing cause of transplant failure associated with HCMV infections, in particular after prolonged antiviral therapy (24). PCZ fully inhibited the replication of viruses with mutations in UL54 gene conferring cross-resistance to GCV and cidofovir or to foscarnet and acyclovir (strains 759'D100 and PFA'D100, respectively, Table 2). Anti-HCMV activity against different strains was found also for MCZ and ECZ (Table 2), two other antifungal drugs emerged for anti-HCMV activity during the drug repurposing screening (12).

Finally, the inhibitory activity of PCZ against HCMV resulted not cell type-dependent, since the EC₅₀ values measured for the TR strain in epithelial (EC₅₀ = 4.2 µM) and endothelial (EC₅₀ = 4.8 µM) cells were in line to that observed in fibroblasts (EC₅₀ = 3.7 µM) (Table 2). Moreover, since TR strain is naturally resistant to GCV and CDV, we obtained further evidence of the activity of PCZ against HCMV clinical strains resistant to DNA polymerase inhibitors.
Taken together these results indicated that PCZ and other antifungals could have a mechanism of action different from that of anti-HCMV drugs targeting the viral DNA polymerase.

**Effects of PCZ treatment on HCMV yield.** PCZ is routinely used as a systemic drug to prevent and treat fungal infections in immunosuppressed patients (25), thus, we decided to focus on this molecule, given that a potential dual antifungal and antiviral effect could be relevant in this clinical setting. To better characterize the anti-HCMV activity of PCZ, we also evaluated its effects on the production of virus progeny in a multi-cycle viral growth experiment. PCZ reduced the production of HCMV infectious progeny in a dose-dependent manner as revealed by virus yield reduction assays (Table 3). In sum, we observed that treatment of HCMV-infected cells with PCZ after infection resulted in the inhibition of viral replication and progeny production.

**Inhibition of human CYP51, a host target of posaconazole, correlates with anti-HCMV activity.** PCZ is known to interfere with different host pathways (26-29), among which there are cholesterol homeostasis and synthesis mediated by human CYP51, the rate-limiting enzyme in late-stage cholesterogenesis (28-30). Thus, we exploited VFV, the most potent enzymatic inhibitor of hCYP51 identified so far (30), to investigate the involvement of hCYP51 during HCMV replication. Like other azolic compounds, VFV inhibits human CYP51 by binding in the enzyme active site and competing with the substrate lanosterol. In enzymatic assays in vitro, both VFV and PCZ inhibited the initial rate of lanosterol conversion catalyzed by purified hCYP51 with IC$_{50}$ values of 0.5 and 8 µM, respectively (Fig. 3A and Table 3). This was not observed with VCZ (IC$_{50}$ >100 µM), which served as a negative control in the enzymatic assays (Fig. 3A and Table 3). When tested by PRA, VFV
caused a dose-dependent inhibitory effect on HCMV replication (Fig. 3B), albeit with an EC₅₀ value higher than that of PCZ (13.3 µM versus 3.3 µM). However, given the highly hydrophobic nature of VFV (LogP 5.4), we reasoned that VFV could be poorly soluble in the semi-solid medium used for PRAs, thus virus yield reduction assays with VFV were also performed. VFV showed indeed a strong and dose-dependent inhibitory effect on infectious virus production with an EC₅₀ in the low-micromolar range (Fig. 3C and Table 3), thus suggesting that hCYP51 enzymatic activity is required for the production of infectious HCMV progeny.

**HCMV infection activates hCYP51 expression.** Since we observed that hCYP51 enzymatic activity is required for HCMV replication, next we investigated whether its expression could be modulated during viral infection. Indeed, under normal conditions (i.e., cells grown in regular cholesterol-containing medium), the cholesterol biosynthetic pathway is not stimulated. To analyze the modulation of hCYP51 promoter upon HCMV infection, we transfected permissive U-373 MG cells with a plasmid encoding a reporter gene under the control of hCYP51 promoter and then infected them with HCMV. As shown in Fig. 4A, infection with HCMV activated hCYP51 promoter by about 40-fold. This upregulation was not observed when the transfected cells were infected with a UV-inactivated virus, which is able to bind and enter into the cells but not to express viral genes, arguing that de novo synthesized HCMV proteins are required for hCYP51 promoter activation (Fig. 4A). Upon infection of serum-fed HFFs, a ~2-fold increase in hCYP51 mRNA level was observed during the early phase of HCMV replication (Fig. 4B) and an accumulation of hCYP51 protein throughout the virus cycle was accordingly detected by both Western blot (Fig. 4C)
and Fig. S1) and immunofluorescence analysis in living cells (Fig. S2). Altogether, these data support the view that HCMV infection activates hCYP51 gene expression.

**Inhibition of hCYP51 enzyme during HCMV replication reduces the infectivity of viral progeny.** As shown above, both VFV and PCZ inhibited hCYP51 enzyme, which catalyzes the rate-limiting step in late cholesterogenesis. Thus, treatment of HCMV-infected cells with these inhibitors should reduce *de novo* cholesterol synthesis during HCMV replication. The intracellular presence of cholesterol during HCMV infection and within the virus particle has been related to the infectivity of HCMV virions (31). We therefore hypothesized that the virus particles produced in cells treated with hCYP51 inhibitors might be less infective. To test this, we determined the particle-to-PFU ratio of cell-free HCMV released from infected HFF cells treated with PCZ, VFV, or DMSO as a control, assuming that each virus particle (infectious or defective) contained one genome. Treatment of HCMV-infected cells for 120 h with either PCZ or VFV significantly reduced both the number of HCMV genomes (Fig. 5A) and the infectivity of viral progeny, with a ~7-10-fold increase in particle-to-PFU ratio with respect to DMSO-treated infected cells (Fig. 5B). Altogether, the results from this section indicated that hCYP51 enzymatic activity is required in the context of productive HCMV replication and could contribute to the generation of infectious HCMV particles.

**GCV and PCZ act synergistically against HCMV replication in infected cells.** We also tested by PRAs the antiviral efficacy of GCV in the absence or the presence of a dose of PCZ (3 µM) approximately equivalent to the mean concentration found in plasma by therapeutic drug monitoring of patients treated with PCZ (25). Noteworthy, in the presence of PCZ, GCV was ~10-fold more potent against HCMV than in the presence of the vehicle.
DMSO (EC$_{50}$ 0.13 µM for the combination of GCV + PCZ versus 1.44 µM for GCV + DMSO, Fig. 6). Considering these results, we investigated further the effects of the combination of PCZ with GCV against the replication of HCMV AD169 by PRAs. As reported in Table 4, the combination of GCV and PCZ resulted in antiviral synergism at all drug combinations tested, since the Combination Index (CI) values calculated by applying the Chou & Talalay method (32) resulted all <0.9 (Table 4). We did not observe any evident cell cytotoxicity when the drugs were tested in combination, thus the synergistic effect on the reduction of viral plaques number was most likely the result of combining two drugs with different targets and mechanisms of action. Beside a reduction in the absolute number, we also observed a clear reduction in the size of the plaques when GCV was used in combination with PCZ. The calculated Dose Reduction Indexes are reported in Table S3. Although future trials will be required to validate this observation in a clinical setting, these results suggest that a combination of GCV and PCZ might represent a new therapeutic strategy for the management of HCMV infections.

### DISCUSSION

Our study stems from the observation of an overrepresentation of drugs belonging to the class of azolic antifungals among the molecules selected in a previous drug repurposing screening aimed at identifying new anti-HCMV compounds (12). Starting from this observation, we report for the first time that posaconazole, a drug already approved and used in both adult and pediatric immunosuppressed patients for prevention and as salvage therapy of fungal infections, is a potent inhibitor of HCMV replication in the low micromolar range.
By characterizing the anti-HCMV profile of PCZ, we found that upon treatment of infected cells with PCZ and VFV, two inhibitors of hCYP51 enzyme, the infectivity of the released HCMV particles is significantly reduced. Azolic antifungals have shown a polypharmacological profile mainly by affecting host cholesterol homeostasis and trafficking (26-29), in addition to be active against several unrelated viruses (11,18-21). In human cells, PCZ is known to interfere with several pathways, such as cholesterol trafficking from lysosomes by inhibiting the Niemann-Pick C1 protein transporter (26) and from ER by inhibiting oxysterol-binding protein (OSBP) cholesterol-shuttling protein (11,19), as well as cholesterogenesis by inhibiting hCYP51 enzyme (29,30). The inhibition of OSBP, the target of PCZ against single-stranded positive RNA viruses, might be however likely excluded as a possible mechanism of anti-HCMV activity of PCZ on the basis of the anti-HCMV activity exhibited also by imidazolic antifungals such as miconazole and econazole (Table 1 and Table 2), which do not bind OSBP (12,19).

The reduced infectivity of HCMV particles released from PCZ-treated cells could be caused by the block of cholesterol trafficking and hCYP51 inhibition caused by the drug, leading to lower levels of available cholesterol. In fact, changes in the cholesterol uptake and efflux have been observed during HCMV infection (31,33), and it has been reported that virion cholesterol content is crucial for the infectivity of HCMV progeny (31). Later during infection, when appropriate levels of new cholesterol molecules could be required by HCMV to produce infectious virions, inhibition of hCYP51-mediated cholesterogenesis exerted by PCZ would thus have a detrimental effect on the infectivity of the released viral progeny. However, this hypothesis remains to be tested. Nonetheless, our data suggest a role of the late cholesterogenesis mediated by hCYP51 in the production of infectious HCMV virions.
Indeed, we found that HCMV induces hCYP51 expression during infection. Importantly, a functional role for hCYP51 in the context of productive HCMV infection was validated by a pharmacological approach with the enzymatic inhibitors VFV and PCZ. Furthermore, the observed decrease in virus yield and in infectivity of virus particles produced upon inhibition of hCYP51 enzymatic activity supports the view that new cholesterol molecules are indeed required for the generation of infectious virus particles. Accumulation of new cholesterol molecules might contribute in conferring appropriate membrane fluidity to the enlarged cytomegalic cell, in the organization of virion, or in the targeting and proper localization of viral proteins within the envelope or mature virus particle. Accordingly, in other virus models, both virion cholesterol content and effective cholesterogenesis have been reported to affect virus infectivity. Depletion of cholesterol during hepatitis B virus infection was shown to induce in fact a topologic change of the large envelope protein that renders the virus non-infectious (34). Interestingly, also HIV-1 Nef protein induces hCYP51 expression to increase de novo cholesterol synthesis and enhance virions infectivity (35), and low levels of cholesterogenesis and cholesterol uptake have been related to a lower HIV trans-infection ability and a slower disease progression in vivo (36).

Posaconazole peak levels (Cmax) in plasma of treated patients either under prophylaxis or treatment of invasive fungal infections depend on a series of different factors, among which there are the formulation, the posology, the diet, and of course the administered dose (37). During prophylaxis in patients at high risk of both fungal and HCMV infections and for therapeutic use in the treatment of mycosis, posaconazole peak levels are reported to be averagely 1.5-2 µg/ml, corresponding to 2.2-2.9 µM (41-42), and thus approximately equal to or below the EC_{50} that we found for posaconazole against...
HCMV (Table 2). However, anti-HCMV activity for posaconazole within a clinically achievable range could be obtained either by synergistic combination with GCV or by developing a better formulation.

We also observed that PCZ exerted anti-HCMV activity against both wild-type clinical isolates and drug-resistant viral strains in a cell-type independent manner. Importantly, we demonstrated that GCV and PCZ act synergistically in inhibiting HCMV replication in infected cells with a combination effect ranging from moderate to very strong synergism. The analysis of our data with Calcusyn software allowed the determination of the simulated Dose Reduction Index (DRI) for both GCV and PCZ. DRI estimates the extent to which GCV levels may be reduced when used in synergistic combination with PCZ to achieve effect levels compared with GCV used alone (32). For example, 90% inhibition of HCMV replication may be potentially obtained by reducing by 10- and 6-fold GCV and PCZ, respectively (Table S3), a condition that could be clinically achievable in treated patients. However, this simulation remains to be clinically tested in vivo.

In conclusion, our study suggests that repurposing of posaconazole against HCMV both alone and in combination with GCV could foster the development of new antiviral strategies against this important viral pathogen, exploiting its dual antimicrobial activity, and contribute to understand how HCMV manipulates host pathways for a productive replication.

MATERIALS AND METHODS

Compounds. Ganciclovir (GCV), foscarnet (FOS), and all the antifungal drugs were from Sigma-Aldrich. Cidofovir (CDV, Vistide) was from Gilead Sciences. VFV ((R)-N-(1-
(3,4’-difluoro-[1,1’-biphenyl]-4-yl)-2-(1H-imidazol-1-yl)ethyl)-4-(5-phenyl-1,3,4-oxadiazol-2-yl)benzamide) was synthesized at Vanderbilt University as described (43). For cellular assays, 100× stock of VFV was prepared in 25% dimethylsulfoxide (DMSO)/34% aqueous 2-hydroxypropyl-β-cyclodextrin (v/v) purchased from Sigma.

**Cells and viruses.** Human Foreskin Fibroblast (HFF), ARPE-19, and U-373 MG were all from the American Type Culture Collection (ATCC) and were cultured in Dulbecco modified Eagle’s medium (DMEM) (Life Technologies) supplemented with 10% fetal bovine serum (FBS, Life Technologies), 100 U/ml penicillin, and 100 µg/ml streptomycin sulfate (P/S, both from Life Technologies). Human dermal microvascular endothelial cells (HMVECs) (CC-2543) were obtained from Clonetics and cultured in endothelial growth medium (EGM) (Clonetics). All cell cultures were maintained at 37°C in a humidified atmosphere supplemented with 5% CO₂.

HCMV (strain AD169) was purchased from the ATCC. HCMV TB40E-UL32-EGFP (kindly provided by C. Sinzger, University of Ulm, Germany) was previously described (44) as well as HCMV VR1814 (kindly provided by G. Gerna, IRCCS Policlinico San Matteo, Pavia, Italy) recovered from a cervical swab from a pregnant woman (45). HCMV 388438U clinical isolate was collected from a urine sample at the Microbiology and Virology Unity of Padua University Hospital (Italy) and was under passage 4 after primary isolation. HCMV strains resistant to antiviral drugs were obtained from the NIH AIDS Research and Reference Reagent Program (Rockville, MD) and previously described (46). HCMV TR was reconstituted by transfecting HFFs with the corresponding TR-BAC that was prepared from the TR clinical strain resistant to GCV and CDV and isolated from an ocular specimen (47).
Reconstitution of BAC-derived TR strain in fibroblasts generated infectious virus that retains the ability to infect both endothelial and epithelial cells (48).

**Plaque reduction assays.** Plaque reduction assays (PRAs) with HCMV were performed as previously described (49). Briefly, HFF, ARPE-19, and HMVEC cells were seeded at a density of $1.5 \times 10^5$ cells per well in 24-well plates. The next day, the cells were infected at 37°C with 80 Plaque Forming Unit (PFU) per well of the different viruses in serum-free DMEM. At 2 h p.i., the inocula were removed, cells were washed, and media containing various concentrations of each compound, 2% FBS, and 0.6% methylcellulose were added. After 10 days of incubation at 37°C, cell monolayers were fixed and stained with crystal violet, and viral plaques were counted.

**Cytotoxicity assays.** The cytotoxicity of tested compounds was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT; Sigma-Aldrich) method as described previously (50).

**Virus yield reduction assays.** For virus yield reduction assays, HFF cells were plated at $2 \times 10^4$ cells per well in 96-well plates, incubated overnight, and infected the next day with HCMV AD169 at MOI = 0.1 PFU/cell. After virus adsorption for 2 h at 37°C, cells were washed and incubated with 0.2 ml of fresh medium containing 5% FBS in the absence or in the presence of test compounds. Plates were incubated for 5 days at 37°C, and then subjected to one cycle of freezing and thawing. Titres were determined by transferring 0.1 ml aliquots from each well to a fresh 96-well monolayer culture of HFF cells, followed by 1:5 serial dilutions across the plate. Cultures were incubated for 7 days and at the end of incubation they were fixed and stained, and the numbers of plaques were determined.
**Enzymatic assays in vitro.** Recombinant human CYP51 and its redox partner NADPH-cytochrome P450 reductase (CPR) were expressed in *Escherichia coli* and purified as described previously (30). The standard reaction mixture contained 0.5 µM hCYP51 and 1.0 µM CPR, 100 µM L-α-1,2-dilauroyl-sn-glycerophosphocholine, 0.4 mg/ml isocitrate dehydrogenase, and 25 mM sodium isocitrate in 50 mM potassium phosphate buffer (pH 7.2) containing 10% glycerol (v/v). After addition of the radiolabeled ([3-3H]) lanosterol (~4,000 dpm/nmol; dissolved in 45% HPCD, w/v, final concentration 50 µM) and inhibitors (concentration range 0.1 - 20 µM), the mixture was preincubated for 30 s at 37 °C in a shaking water bath, the reaction was initiated by the addition of 100 µM NADPH and stopped by extraction of the sterols with 5 ml of ethyl acetate. The extracted sterols were dried, dissolved in methanol, and analyzed by a reversed-phase HPLC system (Waters) equipped with a β-RAM detector (INUS Systems) using a NovaPak octadecylsilane (C18) column and a linear gradient water/acetonitrile/methanol (1.0:4.5:4.5, v/v/v) (solvent A) to CH3OH (solvent B), increasing from 0 to 100% B for 30 min at a flow rate of 1.0 ml/min. The IC50 values were calculated using GraphPad Prism 6, with the percentage of lanosterol converted being plotted against inhibitor concentration and the curves fitted with non-linear regression (log(inhibitor) vs. normalized response - variable slope).

**Plasmids.** The pCYP51-luc plasmid, which contains the −314/+343 human CYP51 (hCYP51) gene promoter region upstream of the luciferase reporter gene was kindly provided by D. Rozman (Centre for Functional Genomics and Bio-Chips Institute of Biochemistry, Faculty of Medicine University of Ljubljana, Slovenia) and was previously described (51). pGAPDH-eGFP plasmid, which contains the promoter region of cellular
GAPDH gene upstream of the enhanced Green Fluorescent Protein (eGFP) gene was previously described (41) and used as a control of transfection efficiency.

Cell transfections and HCMV infection. For the transfection/infection experiments with HCMV, U-373 MG cells were grown on 24-well plates and co-transfected using calcium phosphate (Calcium Phosphate Transfection Kit, Sigma) with 1 µg of pCYP51-luc plasmid along with 0.2 µg of pGAPDH-eGFP plasmid as a control to normalize transfection efficiency. The next day, transfected cells were either mock-infected or infected with HCMV AD169 at MOI = 0.5 PFU/cell for 2 h and then incubated with 5% FBS-containing medium. At 48 h post-infection, luciferase activity as well as eGFP expression were measured. For all the experiments, the values were normalized by dividing the values obtained for luciferase (LU) by the fluorescence units (FU) obtained for eGFP expression and expressed as relative luciferase units (RLU). For UV-inactivation, a procedure previously described was followed (52). Briefly, HCMV diluted in serum-free DMEM was exposed for 8 min at a distance of 4 cm under a UV-light (VL-6MC, 254 nM, 6w). Inactivation of the virus was assessed by immunofluorescence.

Quantification of gene expression. HFF cells were seeded in 6-well plates at $6 \times 10^5$ cells/well and incubated o/n at 37°C. In case of infection, the next day they were infected with HCMV AD169 at MOI = 1 PFU/cell for 2 h and then incubated with 5% FBS-containing medium. Total RNA was extracted from samples collected at different times p.i. using a total RNA Purification Plus Kit (Norgen Biotek) according to the manufacturer’s protocol. cDNA was generated from RNA (2 µg) using random primers (Applied Biosystems) and M-MLV reverse transcriptase (Applied Biosystems). qPCR was performed with SYBR green reagent (Applied Biosystems) according to the manufacturer’s instructions.
on a 7900 HT Fast Real-Time PCR System (Applied Biosystems) using primers for *hCYP51*, *GAPDH*, and HCMV *UL54* genes (sequences reported in Table S1). The relative changes in gene expression were calculated by means of the $\Delta\Delta^{	ext{Ct}}$ method (53) using *GAPDH* to normalize data.

**Western Blot.** For the analysis by Western blot of the induction *hCYP51* during HCMV infection, subconfluent HFF cells in 6-well plates were infected with HCMV AD169 at a MOI = 0.5 PFU/cell. Whole-cell protein extracts were prepared at different times as previously described (12) and then analyzed by Western blot with different antibodies listed in Table S2. Immunocomplexes were detected with the appropriate secondary anti-immunoglobulin Abs conjugated to horseradish peroxidase (Life Technologies). Densitometry analysis was performed with ImageJ software (https://imagej.nih.gov/ij/).

**Immunofluorescence and confocal microscopy analysis.** For confocal laser-scanning microscopy analysis, HFFs were infected with HCMV AD169 at an MOI = 0.25 PFU/cell. At different times p.i., cells were fixed with 4% paraformaldehyde in PBS 1× for 15 min at room temperature and then permeabilized with 0.1% Triton X-100 in PBS for 20 min at RT. After washing extensively with PBS, cells were incubated first with 4% FBS in PBS for 1 h at room temperature and then with different primary antibodies (listed in Table S2) diluted in FBS 4% in PBS 1× for 1 h at 37°C under shaking. Cells were then washed extensively with 4% FBS in PBS 1× and incubated with secondary fluorochrome-conjugated antibodies (listed in Table S2) for 1 h at 37°C. Nuclei were stained by incubation for 20 min with Draq5 (1:8,000 in PBS 1×). Cells were imaged using a Nikon Eclipse Ti-E microscope.

**Particle-to-PFU ratio determination.** To determine the particle-to-PFU ratio of HCMV produced in the presence of test compounds, HFFs were seeded at $2 \times 10^4$ cells per
well in 96-well plates, incubated overnight, and infected the next day with HCMV AD169 at MOI = 0.5 PFU/cell. After virus adsorption for 2 h at 37°C, cells were washed and incubated with 0.2 ml of fresh medium containing 5% FBS in the presence or in the absence of test compounds. Plates were incubated for 5 days at 37°C. At the end of the incubation, 0.05 ml of supernatants were used to determine the number of virus particles that were produced under the different experimental conditions, while 0.05 ml were titrated on fresh monolayers of HFF cells as previously described, to determine the number of PFUs present in the same volume of supernatant. For virus particles determination, 0.05 ml of supernatants were incubated with 0.2% SDS and proteinase K for 1 h at 56°C and then for 15 min at 95°C to inactivate proteinase K. Then, viral DNA was extracted with DNA purification kit (Promega) and quantified by qPCR as described below. The particle-to-PFU ratio was determined by dividing the number of HCMV genomes by the number of PFU determined in the same volume of supernatant derived from the same sample.

**Quantification of viral genomes.** To quantify the HCMV genomes in 0.05 ml of supernatants derived from the different samples collected at 120 h p.i., quantitative Real-Time PCR (qPCR) was performed as previously described (46). The number of viral genomes was normalized to the cellular β-globin gene copies. The sequences of the oligonucleotides used are listed in Table S1.

**Drug combination studies.** To evaluate the combined effects of PCZ and GCV on HCMV AD169 replication, plaque reduction assays were performed as described above using 0.25x, 0.50x, 1x, 2x, and 4x EC50 for each combination of PCZ and GCV at equipotent ratio. The 2-drug combination effects were assessed using the Chou-Talalay method (32).
based on mass-action law based dynamic theory computed in the CalcuSyn software version 2.0 (Biosoft, Cambridge, UK).

Statistical analysis. All statistical analyses were performed using GraphPad Prism version 6.0.

SUPPLEMENTAL MATERIAL
Supplemental material to this article may be found at journal website.

ACKNOWLEDGMENTS
This work was supported by University of Padua (STARS Consolidator Grant FINDER to B.M.); by Associazione Italiana per la Ricerca sul Cancro (AIRC, grant n. IG18855 to A. Loregian); by Ministero dell’Istruzione, dell’Università e della Ricerca, Italy (PRIN 2017 n. 2017KM79NN to A. Loregian, and PRIN 2017 n. 2017HWPZZZ to A. Luganini); by British Society for Antimicrobial Chemotherapy, UK (grant BSAC-2018-0064 to A. Loregian); by University of Turin (Local Research Funds to G.G. and A. Luganini); by Fondazione Umberto Veronesi (to M.C.); and by a grant from the National Institutes of Health, USA (GM067871) to G.I.L. The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication. We thank D. Rozman, G. Pari, and M. Mach for providing plasmids; C. Sinzger and G. Gerna for providing some of the viruses used in this study, and L. Messa and T. Hargrove for experimental assistance.

DECLARATION OF INTERESTS
B.M., A. Luganini, G.G., and A. Loregian have filed a provisional patent on the use of posaconazole alone and in combination with ganciclovir for the treatment of pathological condition(s) associated with cytomegalovirus infection.

REFERENCES


FIGURE LEGENDS

FIG 1 Susceptibility of HCMV to approved azolic antifungals. Plaque reduction assays were performed in HFF infected with HCMV and treated with different doses (from 0.1 to 25 µM) of the indicated test compounds or GCV as a control. (A) Dose-dependent inhibition of HCMV AD169 replication by PCZ and KTZ. (B) Absence of significant inhibition of HCMV AD169 replication by FCZ, ITZ, and VCZ. (ITZ could be tested only up to 10 µM due to solubility issues). Graph represents mean ± SD of n ≥ 3 independent experiments in duplicate.
FIG 2 Dose-dependent inhibition of the replication of indicated HCMV strains by posaconazole. Plaque reduction assays were performed in HFF infected with the indicated HCMV strains and treated with different doses (from 0.1 to 25 µM) of PCZ. Graphs represent mean ± SD of n = 3 independent experiments in duplicate.

FIG 3 Inhibition of host hCYP51 affects HCMV replication. (A) Inhibition of enzymatic activity of purified hCYP51 by VFV, PCZ, and VCZ (2 min reaction). Graph represents the mean ± SD of n = 3 independent experiments in duplicate. (B) Plaque reduction assays were performed in HFF infected with HCMV AD169 and treated with different doses (from 0.1 to 25 µM) of hCYP51 inhibitor VFV. Graphs represent the mean ± SD of n ≥ 3 independent experiments in duplicate. (C) Dose-dependent inhibition by VFV of virus progeny production in HCMV-infected HFFs as determined by virus yield reduction assays. Graph represents the mean ± SD of n = 4 independent experiments in duplicate.

FIG 4 hCYP51 expression is activated during HCMV infection. (A) Activation of hCYP51 promoter in U-373 MG cells mock-infected or infected with either HCMV AD169 or UV-inactivated HCMV. Reported data are expressed as Relative Luciferase Units (LU/FU, RLU), which are the luciferase units normalized to the fluorescence units derived from the expression of the co-transfected eGFP reporter gene. Graph represents the mean ± SD of n = 3 independent experiments in duplicate. Data were analyzed by a one-way ANOVA followed by Tukey’s multiple comparison tests. ***p≤0.0001; ****p<0.0001. (B) Analysis of hCYP51 mRNA levels upon HCMV infection of HFF cells determined by qPCR at the indicated times. The mRNA levels of UL54 were detected as a control for the progression of the infection at 24 and 48 h p.i. mRNA levels were normalized to cellular GAPDH and gene expression was reported as relative quantification (RQ) compared to
calibrator sample (mock-infected cells for hCYP51 and HCMV-infected cells at 24 h p.i. for UL54). Graph represents the mean ± SD of n = 3 independent experiments in duplicate. (C) Analysis of hCYP51 and viral proteins expression during HCMV replication. Host hCYP51 protein and viral IE antigens (IEA) were detected by Western blot both in mock-infected HFFs (M) and in HFFs infected with HCMV at an MOI = 0.5 PFU/cell at the indicated h p.i. Detection of host β-actin was used as a loading control. Molecular weights in kDalton are indicated on the left. Image of a representative experiment is showed.

FIG 5 Effects of hCYP51 enzymatic activity inhibition on HCMV replication and infectivity. (A) Pharmacological inhibition of hCYP51 reduces the number of HCMV genomes. HFF cells infected with HCMV at MOI = 0.5 PFU/cell were treated with 10 µM PCZ or VFV, or 0.1% DMSO as a control for 120 h. HCMV genome copies in the supernatant of each sample were then determined by qPCR. Graph represents the mean ± SD of n = 3 independent experiments in quadruplicate. Data were analyzed by a one-way ANOVA followed by Dunnett’s multiple comparison test. ***p<0.001; **p<0.005 compared to control (DMSO-treated, infected sample). (B) Pharmacological inhibition of hCYP51 reduces the infectivity of viral particles. Particle-to-PFU ratios were obtained by dividing the number of HCMV particles collected from supernatants derived from HFFs infected at MOI = 0.5 PFU/cell and treated with test compounds (determined by qPCR) by the viral titers obtained in the same sample volume (determined by titration on fresh monolayers). Graph represents the mean ± SD of n = 3 independent experiments in quadruplicate. Data were analyzed by a one-way ANOVA followed by Dunnett’s multiple comparison tests. *p<0.05; **p<0.005, compared to control (DMSO-treated, infected sample).
FIG 6 Therapeutic dose of posaconazole enhances anti-HCMV activity of ganciclovir.

Antiviral efficacy of GCV against HCMV AD169 in the absence (+ DMSO) or the presence (+ PCZ) of 3 μM PCZ as determined by PRA. Graph represents the mean ± SD of n ≥ 3 independent experiments in duplicate.
Table 1. Antiviral activity of antifungal drugs against HCMV AD169

<table>
<thead>
<tr>
<th>Compound (Abbreviation)</th>
<th>EC$_{50}^b$ (µM)</th>
<th>CC$_{50}^c$ (µM)</th>
<th>SI$^d$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clotrimazole (CTZ)$^a$</td>
<td>0.8 ± 0.6</td>
<td>40 ± 28</td>
<td>50</td>
</tr>
<tr>
<td>Econazole (ECZ)$^a$</td>
<td>5.7 ± 1.7</td>
<td>85 ± 13</td>
<td>17</td>
</tr>
<tr>
<td>Fluconazole (FCZ)</td>
<td>&gt; 25</td>
<td>&gt;250</td>
<td>&gt;10</td>
</tr>
<tr>
<td>Itraconazole (ITZ)</td>
<td>&gt;10</td>
<td>N.D.</td>
<td>N.D.</td>
</tr>
<tr>
<td>Ketoconazole (KTZ)</td>
<td>14.4 ± 4.6</td>
<td>116 ± 6</td>
<td>8</td>
</tr>
<tr>
<td>Miconazole (MCZ)$^a$</td>
<td>3.2 ± 0.8</td>
<td>55 ± 16</td>
<td>17</td>
</tr>
<tr>
<td>Posaconazole (PCZ)</td>
<td>3.3 ± 0.5</td>
<td>&gt;250</td>
<td>&gt;76</td>
</tr>
<tr>
<td>Voriconazole (VCZ)</td>
<td>&gt; 25</td>
<td>&gt;250</td>
<td>&gt;10</td>
</tr>
<tr>
<td>Ganciclovir (GCV)</td>
<td>2.3 ± 0.6</td>
<td>&gt;500</td>
<td>&gt;217</td>
</tr>
</tbody>
</table>

$^a$ Reported in Reference 12.
$^b$ 50% Effective Concentration, the compound concentration that inhibits 50% of plaque formation, as determined by PRAs against HCMV AD169 in HFF cells. Reported values represent the means ± SD of data derived from n ≥ 3 independent experiments in duplicate. GCV was included as a positive control.
$^c$ Compound concentration that produces 50% of cytotoxicity, as determined by MTT assays in HFF cells. Reported values represent the means ± SD of data derived from two independent experiments in duplicate.
$^d$ SI, Selectivity Index (determined as the ratio between CC$_{50}$ and EC$_{50}$).
N.D., Not Determined.
Table 2. Antiviral activity of antifungal drugs against different HCMV strains in different cell types

<table>
<thead>
<tr>
<th>HCMV strain</th>
<th>Cell type</th>
<th>Antiviral activity EC_{50} (µM)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>ECZ</td>
<td>MCZ</td>
</tr>
<tr>
<td>TB40-UL32-EGFP</td>
<td>HFF</td>
<td>4.5 ± 0.7</td>
<td>3.8 ± 0.4</td>
</tr>
<tr>
<td>VR1814</td>
<td>HFF</td>
<td>3.9 ± 2.1</td>
<td>4.3 ± 1.1</td>
</tr>
<tr>
<td>388438U</td>
<td>HFF</td>
<td>N.D.</td>
<td>N.D.</td>
</tr>
<tr>
<td>759'D100</td>
<td>HFF</td>
<td>4.3 ± 1.1</td>
<td>4.5 ± 1.8</td>
</tr>
<tr>
<td>GDG'P53</td>
<td>HFF</td>
<td>3.4 ± 0.9</td>
<td>2.6 ± 0.3</td>
</tr>
<tr>
<td>PFA'D100</td>
<td>HFF</td>
<td>4.2 ± 0.1</td>
<td>3.7 ± 0.6</td>
</tr>
<tr>
<td>TR</td>
<td>HFF</td>
<td>N.D.</td>
<td>N.D.</td>
</tr>
<tr>
<td>TR</td>
<td>ARPE-19</td>
<td>N.D.</td>
<td>N.D.</td>
</tr>
<tr>
<td>TR</td>
<td>HMVEC</td>
<td>N.D.</td>
<td>N.D.</td>
</tr>
</tbody>
</table>

* 50% Effective Concentration, the compound concentration that inhibits 50% of plaque formation, as determined by PRAs in HFFs, and for TR strain also in epithelial (ARPE-19) and endothelial (HMVECs) cells.

_{b} Reported values represent the means ± SD of data derived from n ≥ 3 independent experiments in duplicate.

_{b} GCV was used as a control for all strains except for PFA’D100, for which FOS was used.

_N.D._, Not Determined.
Table 3. Activity of posaconazole and VFV in virus yield reduction assays and in enzymatic assays in vitro

<table>
<thead>
<tr>
<th>Compound</th>
<th>Antiviral Activity (μM)</th>
<th>Inhibitory Activity (μM)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>EC₅₀ᵃ</td>
<td>EC₉₀ᵇ</td>
</tr>
<tr>
<td>PCZ</td>
<td>2.2 ± 1.1</td>
<td>7.1 ± 1.1</td>
</tr>
<tr>
<td>VFV</td>
<td>1.2 ± 0.9</td>
<td>10.1 ± 1.3</td>
</tr>
<tr>
<td>VCZ</td>
<td>N.D.</td>
<td>N.D.</td>
</tr>
</tbody>
</table>

ᵃ 50% Effective Concentration, the compound concentration that inhibits 50% of virus yield, as determined by titration in HFF cells. Reported values represent the means ± SD of data derived from n = 4 independent experiments in duplicate.

ᵇ 90% Effective Concentration, the compound concentration that inhibits 90% of virus yield, as determined by titration in HFF cells. Reported values represent the means ± SD of data derived from n = 4 independent experiments in duplicate.

ᶜ 50% Inhibitory Concentration, the compound concentration that causes a 50% decrease in the rate of lanosterol conversion, as determined by reconstitution of the hCYP51 activity in vitro, 2 min reaction. Reported values represent the means ± SD of data derived from n = 3 independent experiments in duplicate and calculated using GraphPad Prism 6.0 (dose-response – inhibition).

N.D., Not Determined.
Table 4. Analysis of the effects of the combination of GCV and PCZ against HCMV replication

<table>
<thead>
<tr>
<th>GCV/PCZ combination at equipotent ratio (fold of EC_{50})</th>
<th>CI^b</th>
<th>Drug Combination effect^c</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.25</td>
<td>0.625 ± 0.169</td>
<td>Synergism</td>
</tr>
<tr>
<td>0.5</td>
<td>0.780 ± 0.031</td>
<td>Moderate synergism</td>
</tr>
<tr>
<td>1</td>
<td>0.353 ± 0.278</td>
<td>Synergism</td>
</tr>
<tr>
<td>2</td>
<td>0.075 ± 0.039</td>
<td>Very strong synergism</td>
</tr>
<tr>
<td>4</td>
<td>0.064 ± 0.042</td>
<td>Very strong synergism</td>
</tr>
</tbody>
</table>

^a Fold of 50% Effective Concentration for GCV/PCZ yielding an equipotent concentration ratio between the two combined drugs. The EC_{50} values was determined by PRAs against HCMV AD169 in HFF cells for each drug alone or in combination at concentrations starting from 4-fold to 0.25-fold the equipotent ratio of the drugs considering ratio 1:1.33, approximated values from Table 1.

^b Combination Index, obtained by computational analysis with CalcuSyn software. Reported values represent means ± SD of data derived from n = 3 independent experiments in triplicate.

^c Drug combination effect defined as: very strong synergism for CI<0.1; strong synergism for 0.1<CI<0.3; synergism for 0.3<CI<0.7; moderate synergism for 0.7<CI<0.9, according to (32).
Figure 1

A

B

Plaque formation (% of control)

log [Compound], µM

PCZ EC_{50} 4.0 µM
KTZ EC_{50} 14.4 µM
GCV EC_{50} 2.7 µM

FCZ EC_{50} >25 µM
ITZ EC_{50} >10 µM
VCR EC_{50} >25 µM
GCV EC_{50} 2.5 µM
Figure 2

![Graph showing plaque formation](http://aac.asm.org/)

- Horizontal axis: log [PCZ], µM
- Vertical axis: Plaque formation (% of control)

Legend:
- TB40
- VR1814
- 388438U
- TEO/100
- PFA/100
Figure 3

![Graph showing data for substrate conversion, plaque formation, and HCAV titre (% of control) against log [ Compound], µM.]
Figure 4

A

B

C

Normalized CYP51 promoter activity

RQ (relative to control)

hCYP51

UL54

h.p.i.

66

52

37

M 24 48 72

IEA

hCYP51

β-actin

M 24 48 72 h.p.i.

Figure 4